Molecular Therapy — Nucleic AcidsCancer BiologyPeer-reviewed journal article
Synergic microRNAs suppress human glioblastoma progression by modulating clinically relevant targets
Silvia RancatiiD, Rui Cruz PereiraiD, Michele SchlichiD, Stefania SgroiiD, Silvia BeatiniiD, Letizia La RosaiD, Lidia GiantomasiiD, Roberta Pelizzoli, Clarissa BracciaiD, Andrea Di FonzoiD, Carlotta SpattiniiD, Kiril TuntevskiiD, Amanda Lo VaniD, Meritxell Pons‐EspinaliD, Anna Lisa PalangeiD, Adriana Bajetto, Antonio DagaiD, Andrea ArmirottiiD, Tullio FlorioiD, Paolo DecuzziiD, Davide De Pietri TonelliiD
Abstract
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by therapy-resistant glioma stem-like cells (GSCs) and extensive infiltration into surrounding brain tissue. MicroRNAs (miRNAs) are post-transcriptional regulators of oncogenic pathways, but their tumor-suppressive function is frequently lost in GBM. This study explores a multimodal therapeutic approach by restoring a combination of miRNAs to exploit their synergistic effects against GBM. Using patient-derived GBM cells cultured under stem cell-permissive conditions, we demonstrate that miRNA restoration reduces tumor growth, limits invasiveness, stemness and enhances sensitivity to temozolomide. In vivo studies in an orthotopic xenograft mouse model of GBM confirm the therapeutic efficacy and low toxicity of the nanoformulated miRNAs, following local injection. Multi-omics and computational analyses on different GBM subtypes reveal that these miRNAs synergistically suppress tumor-promoting extracellular matrix interactions, particularly through the collagen pathway, and downregulate genes associated with GBM progression. The identified miRNA targets correlate with glioma grade and poor patient prognosis, further underscoring their therapeutic potential. These findings highlight the promise of combinatorial miRNA therapy as a novel strategy for GBM treatment and suggest new molecular targets for theragnostic development.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 3
- FWCI
- 1.36
- Field percentile
- top 18%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery and therapeutic exploitation of Master Regulatory miRNAs in Glioblastoma
Shekhar Saha, Ying Zhang, … Roger Abounader·bioRxiv·Apr 1, 2025
- MicroRNA miR-100 decreases glioblastoma growth by targeting SMARCA5 and ErbB3 in tumor-initiating cells
Bahauddeen M. Alrfaei, Paul A. Clark, … John S. Kuo·Technology in Cancer Research & TreatmentPeer-reviewed·Jan 1, 2020
- Glioblastoma Drives Protease-Independent Extracellular Matrix Invasion of Microglia
Chia-Wen Chang, Ashwin A. Bale, … Brendan A.C. Harley·Materials Today BioPeer-reviewed·Jan 9, 2025
- Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model
J.-W. E. Chen, J. C. Lumibao, … B. Harley·bioRxiv·Aug 6, 2020
- A microRNA-based Therapy against Human Medulloblastoma Validated in a Xenotransplant Model using Wild-Type Mouse Embryos
Carlotta Spattini, Letizia La Rosa, … Davide De Pietri Tonelli·bioRxiv·Apr 25, 2025
- Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
Y. Wang, S. Malik, … R. Bahal·Science AdvancesPeer-reviewed·Feb 10, 2023